Infectious Diseases Clinical Trial 20193183
[LCID Study Number: 20193183]
A Randomized Double-blind Placebo-controlled Multicenter Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-Associated Pneumonia (VAP) Caused by S. Aureus
The purpose of this study is to evaluate AR-301 (tosatoxumab) as an adjunctive treatment of ventilator-associated pneumonia (VAP) due to Staphylococcus aureus (S. aureus) in combination with standard of care (SOC) antibiotic therapy in patients with confirmed S. aureus infection.
Disease/Condition: Infectious Diseases
Department: Surgical Critical Care
Location(s): Lahey Hospital & Medical Center (Burlington)
Primary Contact Email: SyedBasit.Haider@lahey.org
